This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to 40 participants diagnosed with ALS.
1. Able to understand and give written informed consent.
2. Male or female participants aged 18 years or greater (inclusive) at the time of ALS
3. Participants whose conditions are defined as "definite ALS" or "probable ALS" or
"possible ALS" diagnostic criteria by the revised El Escorial Criteria as determined
by a neurologist specializing in ALS (e.g., the Principal Investigator or
subinvestigator at the site).
4. Participant is able to daily consume 60 mL of the investigational drug suspension
without substantial dysphagia, OR can intake the drug through a gastrostomy tube.
5. In the judgement of the Investigator, the participant's expected survival is greater
than six- months.
6. Participants who have established care with a neurologist at the specialized ALS
center involved in the study and will maintain this clinical care throughout the
duration of the EAP.
1. Participant is eligible for a clinical study with CNM-Au8 for the treatment of ALS.
2. Participant with a history of any clinically significant or unstable medical condition
based on the Investigator's judgment that may interfere with assessment of the study
3. Based on the investigator's judgment, participants who may have difficulty complying
with the protocol and/or any study procedures.
4. Participant with clinically significant abnormalities in hematology, blood chemistry,
ECG, or physical examination not resolved by the Baseline visit which according to
Investigator can interfere with EAP participation1.
5. Participants with clinically significant hepatic or renal dysfunction or clinical
laboratory findings that would limit the interpretability of change in liver or kidney
function, or those with low platelet counts (< 150 x 109 per liter) or eosinophilia
(absolute eosinophil count of ≥ 500 eosinophils per microliter) at Screening.
6. Participants with a prior history of, or positive serological assay for the presence
of HIV infection, or laboratory evidence of active or chronic infection with hepatitis
C (HCV) or hepatitis B (HBV). Note, participants who have been vaccinated for HBV and
have detectable HB antibodies are not excluded unless positive for surface antigen
7. Participant has participated in any other investigational drug trial (within 4-weeks
prior to screening or at least five-half lives of the investigational product), unless
waived at the discretion of the Sponsor (e.g., for other investigational drug trials
with no known interaction with CNM-Au8).
8. Females who are pregnant or nursing or who plan to get pregnant during the course of
this clinical trial or within 6 months of the end of this trial.
9. Females of child-bearing potential, or men, who are unwilling or unable to use
accepted methods of birth control.
10. History of gold allergy.
This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to forty (40) participants diagnosed with ALS. Safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 treatment in ALS participants will be evaluated. Visits will occur at MGH, remotely over telephone, or via tele-visit. Collection of samples for pharmacokinetic and pharmacodynamic analysis may not be feasible for visits completed remotely. Participants will be screened over up to a 4-week period prior to treatment initiation. Participants who meet the inclusion criteria and none of the exclusionary criteria may be enrolled into the EAP. Participants may initiate treatment on the same day as the Screening visit, provided all inclusion and exclusion criteria have been fulfilled prior to treatment initiation. There will be three study periods: 1. A screening period over up to four (4) weeks (Screening Period); 2. Initial treatment period of twenty-four (24) weeks (Treatment Period 1); a. Additional consecutive optional follow-on treatment periods of twenty-four (24) weeks duration may be offered at the discretion of the Investigator and Sponsor (e.g., Treatment periods 2, 3, 4, 5, 6+) 3. A four (4) week safety follow-up period (End-of-Study [EOS] Assessment). Per protocol all participants will receive open-label oral treatment daily up to 24-weeks during Treatment Period 1. Participants may optionally continue on open-label therapy for up to three additional consecutive 24-week treatment periods (e.g., Treatment Period 2, Treatment Period 3, Treatment Period 4, Treatment Period 5, Treatment Period 6 (n), Treatment Period n+1). At treatment discontinuation or following the end of the participant's final Treatment Period, participants will complete an end of study (EOS) assessment 4-weeks following discontinuation of the investigational drug product. Select visit assessments may be collected remotely, via tele-visit with site staff.
Trial Protocol as Published on Clinicaltrials.gov